---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294973160.md"
description: "Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38."
datetime: "2026-08-05T13:00:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294973160.md)
  - [en](https://longbridge.com/en/news/294973160.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294973160.md)
generator: "portal-rs"
---

# 

Syndax Pharmaceuticals shares are trading lower after the company reported mixed Q2 financial results. Also, HC Wainwright & Co. lowered its price target on the stock from $40 to $38.

### Related Stocks

- [SNDX.US](https://longbridge.com/en/quote/SNDX.US.md)

## Related News & Research

- [SNDX: Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis](https://longbridge.com/en/news/298611451.md)
- [Syndax grants stock options for 175,000 shares to 19 new employees under inducement plan](https://longbridge.com/en/news/298070858.md)
- [Pale Fire Capital SE Sells 158,910 Shares of Syndax Pharmaceuticals, Inc. $SNDX](https://longbridge.com/en/news/297896737.md)
- [6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More](https://longbridge.com/en/news/297855589.md)
- [Structure Therapeutics CSO Lin Xichen reports disposal of common shares worth $275,830.34](https://longbridge.com/en/news/297845317.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**